HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Buy rating and announces Price Target of $18.
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Buy rating and announces Price Target of $18.